Commercial Insight: Top 20 Therapy Cancer Brands - Key brands set to consolidate advantage
By Manjula Menon
Bharatbook.com introduces with a new market report with the detailed information about Commercial Insight: Top 20 Therapy Cancer Brands - Key brands set to consolidate advantage as competition intensifies : http://www.bharatbook.com/detail.asp?id=82015
Cancer therapy brand sales totaled over $30 billion in the seven major markets in 2007, growing by 20.1% since 2006. The high growth of this market makes it attractive to companies keen to emulate the blockbuster status achieved by several brands. However, with several impending patent expiries due, companies will need to work hard to maximize their return throughout the lifecycle of their brands.
Scope of this report
Current and future overview of the cancer therapy brands market in 2007 and 2017
Individual country forecasts for the Top 20 cancer therapy brands in each of the seven major markets
Segmentation and analysis of market dynamics by country sales, drug class, indication, company and impacted events
Detailed product profiles and discussion of assumptions and events used in forecast analysis
Research and analysis highlights
The Top 20 cancer therapy brands in the seven major markets contributed the majority ($26.1 billion, 85%) of cancer therapy brand sales in 2007. It forecasts the total market to grow to $62.4 billion by 2017 at a CAGR of 7%. The Top 20 brands in 2017 will still contribute a high proportion of this (80%) with sales reaching $50.2 billion.
Targeted therapies will increasingly dominate the Top 20 cancer brands leaderboard, accounting for 12 of the Top 20 brands in the seven major markets in 2017. It forecasts Avastin to become the leading cancer therapy brand, facilitated by further indication expansion and high physician familiarity.
Genentech/Roche are the dominant force in the market with an oncology portfolio including the three leading cancer therapy brands (Rituxan, Avastin and Herceptin). The companies are set to continue this dominance, with Rituxan, Avastin and Herceptin forecast to remain the top three brands in 2017, achieving aggregate 7MM sales of over $23 billion.
For more information Kindly visit the website : http://www.bharatbook.com/detail.asp?id=82015
Or Contact us on :
Tel No : (+9122 )27578668 , 27579438
Fax: (+9122 )27579131
Address :
Bharat Book Bureau,
207,Hermes Atrium,
Sector-11
P.O Box 54,
CBD Belapur,
Navi Mumbai - 400614.
About the author
Bharat BooK Bureau is the leading market research information aggregator which provides reports, Company profiles, newletters, country info. and online databases for the past twenty years to corportate, consulting firms, academic institutions, government departments, agencies etc., globally, including India. Bharat Book Bureau provides strategic information tools to the executives, business analysts, and knowledge managers that will help them to probe into and support critical, timely business decisions and strategies. It helps global companies to know different market before starting up business / expanding in different countries across the world. www.bharatbook.com is one stop shop for the business intelligence information requirements. from http://www.FreeArticlesAndContent.com
|
|
Copy This Article
For FREE!!!
You can use this article and copy it on your own website
for free! All you have to do is make sure the article
is copied with no changes and includes the "About
The Author" text. Also please ensure that all url's
are hyperlinked according. Thank you. |
Link To This Article - And We'll
Link Back To Your Website!
You are more then welcome to link to this article! All
you have to do is copy this webpage address from the
address bar and create a link on your website. Please
use the title of this article for your link text. Please
get in contact once you have linked to this article
and we'll link back to you! Thank you. |
|
|
|
Other great articles from this category...
|
Related Sites
|
|
